Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQZI7K)

Drug Name
ISIS 23722 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMQZI7K

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis inhibitor survivin (BIRC5) TTTPU1G BIRC5_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Apoptosis inhibitor survivin (BIRC5) DTT BIRC5 3.945 5.647 3.263 5.957
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Apoptosis inhibitor survivin (BIRC5) DTT BIRC5 1.67E-190 1.63 5.29
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01630733) A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
2 Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.Eur J Cancer.2012 Mar;48(5):763-71.